Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalence Study of Dorzolamide 2% Eye Drops
NCT00878917Phase 3Completed
- Sponsor
- Tiefenbacher
- Start
- Apr 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dorzolamide in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Tiefenbacher. Primary endpoint: Intraocular Pressure at 9 weeks. Started Apr 2009; status: completed.
02
Drugs
dorzolamide
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00878917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00878917.